RESUMO
An orally active dual CysLT1 and CysLT2 antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described. Gemilukast (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compound. Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT1 and human CysLT2, respectively, and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT1-dependent guinea pig asthmatic model. In addition, gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT1- and CysLT2-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi. Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.
Assuntos
Asma/tratamento farmacológico , Butiratos/farmacologia , Butiratos/uso terapêutico , Indóis/farmacologia , Indóis/uso terapêutico , Antagonistas de Leucotrienos/farmacologia , Antagonistas de Leucotrienos/uso terapêutico , Receptores de Leucotrienos/efeitos dos fármacos , Animais , Disponibilidade Biológica , Cães , Cobaias , Humanos , Antagonistas de Leucotrienos/farmacocinética , RatosRESUMO
A potent, orally available dual CysLT1 and CysLT2 receptor antagonist with a dicarboxylic acid is described. 4-(3-(Carboxymethyl)-4-{(E)-2-[4-(4-phenoxybutoxy)phenyl]vinyl}-1H-indol-1-yl)butanoic acid (15: ONO-4310321, IC50: CysLT1=13nM, CysLT2=25 nM) showed excellent pharmacokinetic profiles (%Frat=100) compared with our previously reported compound 1 (%Frat=1.5). In addition, we describe a new rule for dicarboxylic acid derivatives to show good oral bioavailability (%Frat⩾40) in rats (HBDs: ⩽2, ClogP: >6.5 and TPSA: <100). Especially, reduction of only one hydrogen-bond donor (HBDs) showed dramatically improved oral bioavailability. This small change of HBDs in dicarboxylic acid derivatives is generally a very effective modification.
Assuntos
Ácidos Dicarboxílicos/administração & dosagem , Ácidos Dicarboxílicos/farmacologia , Descoberta de Drogas , Antagonistas de Leucotrienos/administração & dosagem , Antagonistas de Leucotrienos/farmacologia , Receptores de Leucotrienos/metabolismo , Administração Oral , Animais , Disponibilidade Biológica , Células CHO , Células CACO-2 , Cricetulus , Ácidos Dicarboxílicos/química , Relação Dose-Resposta a Droga , Células HEK293 , Humanos , Antagonistas de Leucotrienos/química , Estrutura Molecular , Relação Estrutura-AtividadeRESUMO
The benzoxazine derivative, (2S)-4-(3-carboxypropyl)-8-{[4-(4-phenylbutoxy)benzoyl]amino}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid (19, ONO-2050297), was identified as the first potent dual CysLT1 and CysLT2 antagonist with IC50 values of 0.017 µM (CysLT1) and 0.00087 µM (CysLT2), respectively.
RESUMO
Liquid chromatography electrospray ionization mass spectrometry (LC/ESI-MS) to probe the nature of the covalent E-I complex was successfully applied to clarify the mechanism of human sputum elastase (HSE) inhibition by a new inhibitor, ONO-5046. The mass spectrum of the four HSE isozymes displayed their molecular ion peaks at m/z=26,018, 25,929, 25,200, and 25,054, respectively. Immediately after incubation, inactivation of HSE with ONO-5046 increased the four molecular ion peaks by approximately 84 amu, which was assigned to the mass unit of the pivaloyl moiety of ONO-5046. An additional minute of incubation of E-I complex restored the original molecular ion peaks. These observations strongly suggested that ONO-5046 inactivates HSE by a reversible 'acylation-deacylation' mechanism.
